Here, we evaluated the prognostic value of BRF2 expression in patients with resectable NSCLC and found that high expression of BRF2 in NSCLC predicted decreased overall 5-year survival and a higher risk of recurrence. Here, BRF2 is linked to non-small cell lung carcinoma.